Mar 19 |
IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington
|
Mar 15 |
Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®
|
Mar 7 |
Clene to Present at the 36th Annual ROTH Conference
|
Feb 29 |
Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024
|
Feb 22 |
Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs
|
Feb 5 |
Clene Inc. announces positive results from CNM-Au8 results from MS trial
|
Jan 24 |
Clene VISIONARY-MS Trial Data May Support CNM-Au8(R) as MS Treatment
|
Jan 10 |
Clene Announces Significant Positive Results from LTE VISIONARY-MS Trial
|
Jan 3 |
Clene's Phase 2 REPAIR-PD and REPAIR-MD Trials Support Advancement to Phase 3
|
Dec 22 |
Clene Announces New Data from HEALEY ALS Platform Trial
|